Loading stock data…
Cytokinetics (CYTK)
$87.26+5.07 (+6.17%)
After Hours$87.75+0.49 (+0.56%)· Last close Jun 29
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $87.26 with a market capitalization of $10.1B. Wall Street consensus targets $105.60 (20 analysts), implying a +21.0% move over the next 12 months. The stock is currently near its 52-week high of $87.35, remaining 35.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $19.36M↑ | $17.75M↑ | $1.94M↓ | $66.77M↑ | $1.58M |
| Gross Profit | $16.80M↑ | -$86.64M↑ | -$97.30M↓ | -$45.78M | $0 |
| Operating Income | -$183.62M↓ | -$178.37M↓ | -$166.75M↓ | -$111.51M↑ | -$155.63M |
| Net Income | -$206.03M↓ | -$183.03M↑ | -$306.18M↓ | -$134.37M↑ | -$161.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
100.37%
Volume
Today's trading volume
3.56M
Recent News
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?
Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, Incorporated’s share was trading at $78.78 as of June 18th. Cytokinetics, Inc. (CYTK) is a cardiovascular-focused biopharmaceutical company developing therapies for diseases of impaired cardiac muscle […]
Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says
Cytokinetics (CYTK) is set up for stronger sales and potential stock gains as its new heart drug Myq
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.